INTERVIEW WITH ARJUN BALAR
A New Era In Systemic Therapies, Pembrolizumab for High Risk Non-Muscle Invasive BCG-Refractory Patients

INTERVIEW WITH CHRISTOPHER LOGOTHETIS
Understanding Differences in Outcomes of Men with Prostate Cancer Based on Race and Ethnicity

INTERVIEW WITH HOWARD SOULE
Advances in PSMA-directed Radionuclide Therapy

INTERVIEW WITH COLIN PRITCHARD
Monoallelic vs Biallelic BRCA2 Alterations, PARP Inhibitors in Prostate Cancer

Videos
State-of-the-industry video lectures by leading urology experts
Featured Videos

EAU 2014 - Prevention of symptomatic skeletal events in patients with genitourinary (GU) tumours and bone metastases treated with denosumab or zoledronic acid - Session Highlights

STOCKHOLM, SWEDEN (UroToday.com) - Patients who develop bone metastases from prostate cancer are at risk for skeletal complications that may seriously impact function and quality of life. Denosumab and zoledronic acid (ZA) are approved for the prevention of skeletal complications from bone metastases in solid tumors. Denosumab has demonstrated superiority over ZA for the prevention of skeletal-related events (SREs). An alternative study endpoint of symptomatic skeletal events (SSE), defined as symptomatic fracture, surgery or radiation to bone, or spinal cord compression) was introduced to describe these bone complications. Dr. K. Fizazi and colleagues compared the benefit of denosumab versus ZA in preventing SSEs in patients with advanced GU tumors and bone metastases.

eauPatients with advanced GU tumors, at least one bone metastasis, and no prior IV bisphosphonate use were randomized to receive either denosumab or ZA every 4 weeks in a double-blind fashion. The risk of first SSE was reduced by 22% in patients treated with denosumab versus ZA. There were also fewer overall SSEs and a longer time to first-and-subsequent on-study SSEs in patients treated with denosumab versus ZA. Fewer SSEs of all types were observed in the denosumab treatment group. Denosumab reduced the risk of skeletal complications in patients with GU cancers and bone metastases regardless of whether the endpoint was defined as SRE or SSE. Because all skeletal complications from bone metastases have the potential to negatively affect patients’ function and quality of life, preventive treatment should be considered even when symptoms are not present.

Presented by K. Fizazi at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden.

Institut Gustave Roussy, University of Paris-Sud, Paris, France

Written by Jeffrey J. Tomaszewski, MD, medical writer for UroToday.com

 

Conference Coverage
 
Recent data from conferences worldwide
  • 2020 Annual Meeting / February 13-15 / San Francisco, CA
  • 2019 Annual Meeting / December 4-6 / Washington, DC
  • 2019 Annual Congress / October 17 - October 20 / Athens, Greece
  • 2019 Annual Meeting / October 3 - October 5 / Aarhus, Denmark
  • 2019 Annual Congress / September 27 - October 1 / Barcelona, Spain
  • 2019 Biennial Meeting / August 29-31 / Basel, Switzerland
  • 2019 Think Tank / August 8-10 / Washington, DC
  • 2019 Annual Meeting / May 31 - June 6 / Chicago, IL
  • 2019 Annual Meeting / May 3-6 / Chicago, IL
Journals
Publications focusing on urologic cancer treatments through original manuscripts